Crohn’s Disease Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies – Centocor Ortho Biotech, UCB Biopharmaceuticals.
DelveInsight’s “Crohn’s Disease Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of the present clinical development scenario and growth prospects across the Crohn’s Disease market. A detailed picture of the Crohn’s Disease pipeline landscape is provided, which includes the disease overview and Crohn’s Disease treatment guidelines.
Key Takeaways from the Crohn’s Disease Pipeline Report
-
Leading Crohn’s Disease companies developing novel drug candidates are Centocor Ortho Biotech, UCB Biopharmaceuticals, and others
-
Promising Crohn’s Disease pipeline therapies in various stages of development include Adalimumab, Infliximab, Certolizumab, and others.
Crohn’s Disease Overview
Inflammatory bowel disease (IBD) is an idiopathic disease caused by a dysregulated immune response to host intestinal microflora. It is a group of inflammatory conditions of the colon and small intestine. In IBD, the immune system responds incorrectly to environmental triggers, which causes inflammation of the gastrointestinal tract. The two major types of IBD are ulcerative colitis (UC), which is inflammation and sores (ulcers) along the superficial lining of the large intestine (colon) and rectum, and Crohn’s disease (CD), which involves inflammation of the lining of the digestive tract and can often involve the deeper layers of the digestive tract. The CD is typically more severe than ulcerative colitis but is slightly less common. The disease can occur at any age, but CD is most often diagnosed in adolescents and adults between the ages of 20 and 30. There are different types of CD, each affecting different parts of the digestive tract including ileocolitis, ileitis, gastroduodenal Crohn’s disease, jejunoileitis, and Crohn’s colitis.
Discover more about the emerging Crohn’s Disease drugs @ Crohn’s Disease Treatment Drugs
Crohn’s Disease Pipeline Therapies and Key Companies
-
Centocor Ortho Biotech: Adalimumab
-
UCB Biopharmaceuticals: Infliximab
And many others
Scope of the Crohn’s Disease Pipeline Report
-
Coverage: Global
-
Key Crohn’s Disease Companies: Centocor Ortho Biotech, UCB Biopharmaceuticals, and others
-
Key Crohn’s Disease Pipeline Therapies: Adalimumab, Infliximab, and others.
Find out more about the Crohn’s Disease treatment options in development @ Crohn’s Disease Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
